Should You Buy Sagility Ltd Shares After Announcing Its Q3 Results?

Synopsis: Sagility Ltd is in focus after Q3 results, with revenue up 36% YoY to ₹1,971 crore and net profit up 24% YoY to ₹268 crore, along with brokerage views on the results and operations.

The shares of a Small-cap company specialising in providing technology-enabled business process management (BPM) services exclusively for the U.S. healthcare industry, are in focus following their Q3 results, and let’s also see the Brokerage viewpoint on the results.

With a market capitalization of Rs. 23,345.78 Crores on Thursday, the shares of Sagility Limited declined upto 4.9 percent, reaching a low of Rs. 49.11 compared to its previous close of Rs. 51.69.

What Happened

Sagility Limited engaged in providing technology-enabled business process management (BPM) services exclusively for the U.S. healthcare industry, is in the spotlight today as it has announced its Q3 results as follows:

Its Revenue from operations rose by 36 percent YoY from Rs. 1,453 Crores in Q3FY25 to Rs. 1,971 Crores in Q3FY26, and it rose by 19 percent QoQ from Rs. 1,658 Crores in Q2FY26 to Rs. 1,971 Crores in Q3FY26.

Its Net Profit YoY rose by 24 percent from Rs. 217 Crores in Q3FY25 to Rs. 268 Crores in Q3FY26, and on a QoQ basis, it rose by 7 percent from Rs. 251 Crores in Q2FY26 to Rs. 268 Crores in Q3FY26. The earnings per share (EPS) for the quarterly period stood at Rs. 0.57, compared to Rs. 0.46  in the previous year’s quarter.

Brokerage Views on Result

Jefferies maintains a Buy rating on the stock with a target price of Rs 70, implying an upside potential of 35 percent from the previous day’s close. The company delivered a strong Q3 performance, posting 17% QoQ constant-currency revenue growth, while EBITDA margins expanded by 110 bps sequentially.

Looking ahead, FY26 revenue growth guidance was raised by 150 bps to 22.5%, and the brokerage expects a robust ~20% recurring EPS CAGR over FY26–28, highlighting continued momentum in earnings and profitability.

Sagility is a technology-enabled, healthcare-focused solutions and services provider that supports U.S.-based payers, providers, and their partners in delivering best-in-class operations, enhancing member and provider experiences, and improving the quality of care, all while ensuring cost-effective financial and clinical outcomes. 

With over two decades of experience, Sagility’s dedicated experts address complex healthcare challenges through deep domain expertise and innovative thinking. The company serves seven of the top health insurance companies in the U.S., utilizing its advanced technology, processes, and solutions to ensure efficient operations and minimize additional administrative costs. The Company delivers these services through its skilled talent pool across five global service delivery centres located in India, the Philippines, the U.S., Jamaica, and Colombia. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Should You Buy Sagility Ltd Shares After Announcing Its Q3 Results? appeared first on Trade Brains.